Acute Bacterial Skin and Skin Structural Infections Market

1
Acute Bacterial Skin and Skin-Structure
Infection (ABSSSI)
Market Insights, Epidemiology and Market
Forecast- 2028
2
Acute Bacterial Skin and Skin-Structure Infection
01
04
02
03
ABSSSI is defined as a bacterial infection of
Skin with a lesion size area of 75 cm2. ABSSSIs
consist of the most frequently diagnosed skin
infections worldwide.  
There are several pathogens that lead to ABSSSIs
like Methicillin sensitive Staphylococcus aureus,
Methicillin resistant Staphylococcus aureus,
Beta-hemolytic Streptococcus, Escherichia coli
and many others.
ABSSSIs may be either community-acquired or
hospital-acquired, and the predisposing factors
include trauma, chronic cutaneous lesions, skin
conditions, edema due to venous insufficiency,
and immunosuppression.
The serious ABSSSIs that need hospitalization for
parenteral antibiotic therapy are identified
based on the nature of the potential causative
pathogens and host factors pointing to the
severity of the disease.

• DelveInsight 2019 All rights reserved

3
ABSSSI Epidemiology
In the United States, more than 15 million
bacterial skin and skin structure infections
occur.
1
2
Acute Bacterial Skin and Skin Structure
Infections total 7MM Incident cases were
7,259,777 in 2017.  
3
There were 1,942,229 male patients and 1,406,442
female cases suffering from ABSSSI in 2017 in the
United States.
4
A total of 1.8 of hospital admissions for 2005
to 2011 were for adult patients with a SSSI
primary diagnosis.

• DelveInsight 2019 All rights reserved

4
ABSSSI Market Outlook
The major subtype of ABSSSI is cellulitis for
which the treatment involves an oral antibiotic
with activity against streptococci. Major
treatment options for mild cases of non-purulent
infections include penicillin, amoxicillin,
amoxicillin-clavulanate, dicloxacillin,
cephalexin, and clindamycin.
ABSSSI treatment usually includes an
antimicrobial therapy, surgical drainage, and
antibiotic therapy. The therapeutic approaches
favored in treating skin infections include
adjunctive therapies, early and appropriate
empiric antibiotic therapy, wound culture with
susceptibility testing and surgical drainage and
debridement.
ABSSSI treatment is quite difficult, as there is
an increased antimicrobial resistance b between
Gram-positive and Gram-negative bacteria with
methicillin-resistant, but the treatment
continues to be antimicrobial therapies combined
with appropriate surgical intervention.
Oral and intravenous options for ABSSSI treatment
for activity against Methicillin resistant
Staphylococcus aureus (MRSA), include several
long-standing therapies, such as
sulfamethoxazole-trimethoprim, clindamycin and
many others.

• DelveInsight 2019 All rights reserved

5
ABSSSI Emerging Drugs and Companies
Drug- Ceftobiprole medocaril Company- Basilea
Pharmaceutica
Drug- Sodium Fusidate Company- Arrevus
Drug- Iclaprim Company- Motif Bio
Drug- Brilacidin Company- Innovation
Pharmaceuticals

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on ABSSSI
Market Insights, Epidemiology and Market
Forecast-2028 please click the link below
Click here
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

7
About DelveInsight
VISION
ABOUT
To be the most trusted market research business
consulting firm in the world and to continue
enable the Pharma Bio-Tech companies to achieve
their goals with the best strategic insight and
competitive solution. The vision also is
inclusive of becoming a one-stop solution
provider for the entire gamut of drug development
process.
DelveInsight is a premier Business Consulting and
Market Research firm focused exclusively on the
life science segment. With a wide array of smart
end-to-end solutions, the firm helps the global
Pharmaceutical and Bio-Tech companies formulate
prudent business decisions for improving their
performances to stay ahead of the competitors.
MISSION
MISSION
To provide insights across the value chain and
helping the organization to take a prudent
business decision through the use and analysis of
actionable market intelligence. The mission also
is to provide the most effective result and
efficient service with utmost client care for
maintaining a long-term relationship with them.

• DelveInsight 2019 All rights reserved

8
About DelveInsight
VISION
ABOUT
MISSION
To be the most trusted market research business
consulting firm in the world and to continue
enable the Pharma Bio-Tech companies to achieve
their goals with the best strategic insight and
competitive solution. The vision also is
inclusive of becoming a one-stop solution
provider for the entire gamut of drug development
process.
DelveInsight is a premier Business Consulting and
Market Research firm focused exclusively on the
life science segment. With a wide array of smart
end-to-end solutions, the firm helps the global
Pharmaceutical and Bio-Tech companies formulate
prudent business decisions for improving their
performances to stay ahead of the competitors.
To provide insights across the value chain and
helping the organization to take a prudent
business decision through the use and analysis of
actionable market intelligence. The mission also
is to provide the most effective result and
efficient service with utmost client care for
maintaining a long-term relationship with them.

• DelveInsight 2019 All rights reserved

9
Service Offerings by DelveInsight
1
OPPORTUNITY ASSESSMENT
5
FORECASTING
2
6
REPORT STORE
PIPELINE
7
3
CONSULTING
PHARMDELVE
MARKET INTELLIGENCE
8
COMPETITIVE ANALYSIS
4

• DelveInsight 2019 All rights reserved

10
Contact Us
blog/delveInsight/
info_at_delveinsight.com
91-11-4568 9769
twitter/delveInsight
LinkedIn/delveInsight
www.delveinsight.com

• DelveInsight 2019 All rights reserved

11
THANK YOU